The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

Darolutamide, also known as Nubeqa and made by Bayer, is recommended in final draft guidance to treat adults with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab with platinum-based chemotherapy within its marketing authorisation for treating primary advanced or recurrent ...

This guidance is a partial review of NICE's diagnostics guidance on tumour profiling tests for guiding adjuvant chemotherapy decisions in early breast cancer (DG34) which made recommendations for ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) ...